
Conversation focused on a topic that is becoming increasingly important in reproductive medicine: how a more personalized understanding of LH activity may influence decision-making in both female and male infertility treatment. With global experts, new clinical frameworks, and emerging evidence now moving closer to daily practice, the discussion was centered not on theory alone, but on what may change in the way specialists think and act in real clinical settings.
Distinguish between measured LH quantity and functional LH bioactivity — and understand why a normal serum result does not guarantee adequate LH action at the follicular level.
Identify the three clinical groups who benefit from LH addition: patients with genetic polymorphisms, patients suppressed by GnRH antagonist or agonist protocols, and women over 35 with declining ovarian reserve.


Use POSEIDON groups 1–4 to classify ovarian response and adapt gonadotropin protocols — including the recognition of LH stagnation as a clinical signal requiring protocol adjustment.
Classify male infertility patients into one of five endocrine phenotypes using FSH, testosterone, and semen analysis — and select the appropriate gonadotropin strategy for each group.
Understand how phenotype-guided hormonal pre-treatment improves sperm retrieval success in non-obstructive azoospermia — based on data from over 600 patients.
Explain the physiological and clinical differences between recombinant LH and HMG, including new 2025–2026 data on euploid blastocyst yield and live birth rates.
Расскажите нам, какие темы для вас важнее всего, какие форматы обучения вы предпочитаете и кого из экспертов хотели бы услышать. Пройдите короткий опрос и повлияйте на будущие образовательные инициативы Sona Academy.
Живая дискуссия о решениях по LH-триггеру и поддержке лютеиновой фазы в современных циклах ВРТ.
Аудио: ENСубтитры: ENUARU1 ч 30 мин
